Ascendis Pharma TransCon PTH Phase 2 Trial Hypoparathyroidism

Phase 2 trial results for TransCon PTH, a long-acting parathyroid hormone therapy for hypoparathyroidism. Study demonstrated 50% of TransCon PTH subjects met primary composite endpoint versus 15% placebo, with 82% able to eliminate conventional therapy. Treatment improved quality of life with favorable safety profile.